Group B. People suffering difficulties requiring
antidepressant/anxyolytic treatment not exposed to
fluvoxamine – (i) at least one ICD-10 F or G30/G31.1 code entry at
any time between January 1 2019 and the date of the index COVID-19
diagnosis, and (ii) no prescription for fluvoxamine issued in the
period between 6 months prior to- and 21 days after the index COVID-19
diagnosis. This also means that they might have been prescribed any
other psychiatric treatment at any time between January 1 2019 and the
date of the index COVID-19 diagnosis.
|
Group C. People free of psychiatric difficulties and
not exposed to fluvoxamine or to any other pharmacological
psychiatric treatment – (i) no ICD-10 F code entries at any time
between January 1 2019 and 21 days after the index COVID-19 diagnosis,
and (ii) no prescriptions for fluvoxamine or any of the other drugs
falling into the Anatomical Therapeutic Chemical codes N05, N06 or
N07B in the period between 6 months prior to- and 21 days after the
index COVID-19 diagnosis.
|
Group A vs. Group B: the two subsets differ regarding the
(presumed) exposure to fluvoxamine in the early phases of COVID-19
disases, while it is reasonable to assume that the burden of
psychiatric difficulties (and related treatments) is generally
similar. This contrast intends to quatify the “effect” of exposure
to (i.e., of the fact of being issued a prescription for) fluvoxamine
in the early phase of COVID-19.
|
Group A vs. Group C: the two subsets differ regarding the
burden of psychiatric conditions and the fact of exposure to
fluvoxamine. This contrast intends to quantify the (joint) “effect”
of psychiatric conditions (including therapies used to treat them) and
of exposure to fluvoxamine.
|
Group B vs. Group C: the two subsets differ regarding the
burden of psychiatric conditions including their respective treatments
(except for fluvoxamine). This contrast intends to quantify the
(joint) “effect” of psychiatric conditions and their respective
tretments, which, however, do not include fluvoxamine.
|